ChAdOx1.tHIVconsv1

ChAdOx1.tHIVconsv1 is an experimental HIV-1 vaccine candidate developed by the University of Oxford. It uses a non-replicating simian adenovirus vector (ChAdOx1) to deliver a conserved mosaic HIV-1 T-cell immunogen (tHIVconsv1) into host cells, aiming to induce strong and broad CD8+ T cell responses against HIV-1. The vaccine is designed as a prime in heterologous prime-boost regimens, often followed by boosts with modified vaccinia Ankara (MVA)-vectored vaccines encoding related antigens. Its primary indication is for the prevention or therapeutic control of HIV-1 infection, and it has been evaluated in Phase 1/2 clinical trials in both healthy volunteers and people living with HIV[3][4][5][6]. The mechanism of action involves delivery of the tHIVconsv1 immunogen to stimulate pathogen-specific cellular immunity[2].